Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference

WALTHAM, Mass., Aug. 11, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Wedbush Securities Life Sciences Management Access Conference at the Le Parker Meridien Hotel, 119 West 56th Street in New York City. The presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. (EDT) in the Lorica Room, located on the second floor.  

Interleukin's management team will be available for one-on-one meetings with investors participating in the Wedbush Securities Life Sciences Management Access Conference.

The presentation will be webcast live at http://www.wsw.com/webcast/wedbush17/iliu/ where it will also be archived for 90 days. The webcast link will also be available through Interleukin's website at http://www.ilgenetics.com.

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information, please visit http://www.ilgenetics.com.

SOURCE Interleukin Genetics, Inc.